Systemic sclerosis & Raynaud's
Beneficial effects of nintedanib on cardiomyopathy in patients with systemic sclerosis: a pilot study
Authors' conclusion
Our data indicate beneficial signals of nintedanib on cardiomyopathy associated with SSc.
Study context
- Population
- Consecutively hospitalized patients with SSc-ILD
- Participants
- 20 consecutive hospitalized patients
- Exposure
- Nintedanib vs treatment without nintedanib or watchful waiting
- Nintedanibn = 10
- Controln = 10reference
- Outcome
- Rate of change in cardiac magnetic resonance (CMR) parametric mapping, including myocardial extracellular volume
- Follow-up
- 6 months
Methodological detailspilot study, non-randomised
- Pilot study
- Non-randomised
Main finding
As reported in the abstract
Myocardial extracellular volume, rate of change
Nintedanib
−1.62%
Control
+2.00%
P = 0.0001
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Change in right ventricular ejection fractionPreferential change in the nintedanib group | P = 0.02 |
Original publication
Beneficial effects of nintedanib on cardiomyopathy in patients with systemic sclerosis: a pilot study. Rheumatology (Oxford). Published 2 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →